Bortezomib (PS-341)

目录号:S1013 别名: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341)是有效的蛋白酶抑制剂,Ki为0.6 nM。它对肿瘤细胞表现出良好的选择性。

规格 价格 库存 购买数量  
RMB 571.94 现货
RMB 2188.92 现货
RMB 5488.32 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献145篇:

客户使用该产品的22个实验数据:

  • Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

  • Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

  • (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • Cell viability of HCT116 cells treated with a single drug or with the addition of leucovorin.

    Sci Rep, 2017, 7(1):682. Bortezomib (PS-341) purchased from Selleck.

    The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

  • PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

  •  

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

    Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

产品安全说明书

Proteasome抑制剂选择性比较

生物活性

产品描述 Bortezomib (PS-341)是有效的蛋白酶抑制剂,Ki为0.6 nM。它对肿瘤细胞表现出良好的选择性。
靶点
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
体外研究

Bortezomib,一种硼酸二肽,是一种26S蛋白酶体的高选择性可逆抑制剂,其作用于错误折叠蛋白的降解,并且对细胞周期的调控是必要的。暴露于Bortezomib能够稳定p21,p27,和p53,以及促凋亡Bid和Bax蛋白,微囊蛋白-1,和抑制剂κB-α,这防止了核因子κB诱导的细胞存活途径的激活。Bortezomib也会促进促凋亡c-Jun-NH2末端激酶,以及内质网应激反应的激活。这些细胞蛋白水平的改变导致对增殖,迁移的抑制,和癌细胞凋亡的促进。[2] Bortezomib能够渗透到细胞,并抑制蛋白酶体介导的细胞内长寿蛋白水解,抑制50%蛋白质水解的浓度为∼0.1 μM。Bortezomib对衍生自美国国家癌症研究所(NCI)多重人类肿瘤的一组60个癌细胞系的IC50值为7 nM。PC-3细胞用Bortezomib (100 nM)处理8小时导致细胞积聚在G2-M期,相应的G1期细胞数量减少。Bortezomib在24和48小时杀死PC-3细胞,IC50分别为100和20 nM。Bortezomib治疗16-24小时后诱导细胞核缩合。Bortezomib在低至100 nM浓度下以时间依赖的方式导致PARP裂解,在处理24小时后产生效果。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 NHX3bmREgXSxdH;4bYMhSXO|YYm= MUm1NEDPxE1? M{TvV|Q5KGh? M37PVWROW09? Mn\XT4ltdHNiY3XscJMh[nlibX;y[UB1cGGwIEm5KS=> MWqxNFQ6QTZ2Mx?=
OVCA 429 M3rh[2Z2dmO2aX;uJGF{e2G7 M4LwNlMxOCCwTR?= MWW0PEBp Mn3WSG1UVw>? MnjBSIl{enWydIOgbY51[WO2IH31cJRq[2WubIXsZZIhfHWvb4Kgd5Bp\XKxaXTz NGXvWm8yODl7OUe2Oi=>
RPMI8226 NUn6emtRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;CNVAxKG6P NVvDNWR{PDhiaB?= Mn;USG1UVw>? NHuxV3RKSzVyPUOwJI5O NGO1OIUyOTNyNkS4PS=>
Dox40 NYTVPVBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH0fHEyODBibl2= NHy3cpc1QCCq MXrEUXNQ NVnZOYpDUUN3ME20NEBvVQ>? NYLqO|c1OTF|ME[0PFk>
MR20 NXPi[npKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moj6NVAxKG6P MmixOFghcA>? MV3EUXNQ NEPMRphKSzVyPUKwJI5O MmfjNVE{ODZ2OEm=
LR5 M2HUemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHHXXkyODBibl2= NXrDTVJoPDhiaB?= MWnEUXNQ NIPrTllKSzVyPUKwJI5O MUGxNVMxPjR6OR?=
U266 M37iOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2G5T|ExOCCwTR?= NEHkZlQ1QCCq NIrvdJNFVVOR NYnCXldvUUN3ME2zJI5O MYqxNVMxPjR6OR?=
IM-9 NHXWVIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3X1SVExOCCwTR?= MYK0PEBp MXPEUXNQ NWW5dXdvUUN3ME22JI5O MXuxNVMxPjR6OR?=
Hs Sultan MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rBUFExOCCwTR?= M4jad|Q5KGh? M4G0c2ROW09? MorlTWM2OD1{MDDuUS=> MYexNVMxPjR6OR?=
PAM-LY2 NXHqV5ZrTnWwY4Tpc44hSXO|YYm= NF;UdFgyODBibl2= NIiySGIyOiCq NEDOVXZFVVOR NIHmWIFKdmirYnn0d{BPTi4QulKgZYN1cX[jdHnvci=> Mlz5NVE{PTB7MUO=
PAM 212 NV3ISXZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7sNVAxKG6P Mmq1O|IhcA>? MV3EUXNQ MXTJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? M4PQT|EyOzVyOUGz
PAM-LY2 Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPnNVAxKG6P NVXtU2Q4PzJiaB?= M1npNWROW09? M3LCZ2lvcGmkaYTzJINmdGxidnnhZoltcXS7 NI[yPYcyOTN3MEmxNy=>
B4B8 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUK3ZY9FOTByIH7N MYS3NkBp M4D5fGROW09? M{HvTGlvcGmkaYTzJINmdGxidnnhZoltcXS7 MnmzNVE{PTB7MUO=
B7E3 M3rNSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[xNFAhdk1? NWDtRXB3PzJiaB?= Mnm2SG1UVw>? M1T3XGlvcGmkaYTzJINmdGxidnnhZoltcXS7 NH\rWG0yOTN3MEmxNy=>
UM-SCC-9 NFrROINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M370RlExOCCwTR?= MVi3NkBp MlOzSG1UVw>? M2TqPGlvcGmkaYTzJINmdGxidnnhZoltcXS7 NVvJfGdNOTF|NUC5NVM>
UM-SCC-11B NVTJeHRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGH5OWsyODBibl2= MYi3NkBp NUHYZWZjTE2VTx?= M2XRWWlvcGmkaYTzJINmdGxidnnhZoltcXS7 NFK2fIkyOTN3MEmxNy=>
H460 MXXGeY5kfGmxbjDBd5NigQ>? NVnP[4hvOTBizszN MWeyOEBp M2LSbWROW09? NIjsbm1KdmS3Y3XzJGJkdC1{IIDoc5NxcG:{eXzheIlwdiCjbnSgZ4xm[X[jZ3WgZ49zemWuYYTl[EB4cXSqIFeyMW0heGijc3WgZZJz\XO2 NXruVFFjOTJ2OUKxNVc>
U266 MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWG1NFAhdmdxbXy= MUC0PEBp MWHEUXNQ Mn\STY5pcWKrdIOgZ4VtdCCpcn;3eIg> MWmxNlY{OTZzOR?=
ARH77 MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUW1NFAhdmdxbXy= M{TWRlQ5KGh? M1PNOGROW09? M{j2dmlvcGmkaYTzJINmdGxiZ4Lve5Rp MYqxNlY{OTZzOR?=
WAD-1 NIPvdnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjLOVAxKG6pL33s MXu0PEBp NHnmSVFFVVOR MkXFTY5pcWKrdIOgZ4VtdCCpcn;3eIg> NHTEZVUyOjZ|MU[xPS=>
U266/LR7 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUS1NFAhdmdxbXy= NEfKVnM1QCCq M{fLd2ROW09? NX21bXF6UW6qaXLpeJMh[2WubDDndo94fGh? M4HaNVEzPjNzNkG5
U266/dox4 NEPweFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPDTHQ2ODBibnevcYw> NV;lcJRDPDhiaB?= MYXEUXNQ NVvJTo5zUW6qaXLpeJMh[2WubDDndo94fGh? MYCxNlY{OTZzOR?=
RPMI8226/LR5 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY[1NFAhdmdxbXy= M2XaU|Q5KGh? NH;IfnBFVVOR Mkm3TY5pcWKrdIOgZ4VtdCCpcn;3eIg> MWGxNlY{OTZzOR?=
H460 M{e4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLtcJg2OTBizszN MV23NkBp MV7EUXNQ Mn\hTWM2OD1zMECgcm0> M4qw[lEzPjNzNkKw
H358 NGmxcJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF20SWMyOCEQvF2= NI[ybVM4OiCq M13QO2ROW09? M1;QZmlEPTB;N{Cgcm0> NVXSemhVOTJ4M{G2NlA>
H322 M3SzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfic2E5OTBizszN NXnPOVB1PzJiaB?= M2fi[2ROW09? MkjuTWM2OD14MkCgcm0> MXWxNlY{OTZ{MB?=
H460 M4LS[2Z2dmO2aX;uJGF{e2G7 M4HHPFExOCCwTR?= NGX0fFUzPCCq MoO2SG1UVw>? NU\3c4hsUW6mdXPld{BIOi2PLYDoZZNmKGG{cnXzeEBidmRidIXieYxqdiCjc4PlcYJtgS2maYPhd5NmdWKueR?= MVmxNlY{OTZ{MB?=
LNCap-Pro5 MYfGeY5kfGmxbjDBd5NigQ>? MX2xJO69VQ>? NXS4VI9lPCCq MWPEUXNQ NFX1fGZUfGGkaXzpfoV{KHB3Mx?= NYfaZ2ZWOTR4MUK1N|I>
T29 MXzBdI9xfG:|aYOgRZN{[Xl? NFvnZmg2OCCwTR?= MofCOFghcCB? NW\Y[IZCTE2VTx?= NEnBeZZKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NFP3WHcyPjd5OEG3PS=>
T29Kt1 M37H[GFxd3C2b4Ppd{BCe3OjeR?= NXrpUZY6PTBibl2= MlKxOFghcCB? NUXJWVRMTE2VTx?= MoDpTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NWWwZ|RkOTZ5N{ixO|k>
HCT116 MUTBdI9xfG:|aYOgRZN{[Xl? M1e3c|UxKG6P MnnpOFghcCB? MX\EUXNQ MYHJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MVKxOlc4QDF5OR?=
HKe-3 NHTYSGhCeG:ydH;zbZMhSXO|YYm= NWTTWWhuPTBibl2= NGPuTpM1QCCqIB?= M1O5eGROW09? Ml71TY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NUm4UJRzOTZ5N{ixO|k>
NB-1691 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fvNFEh|ryP NF\4VJc4OiCq NWnxUoE{UW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEWl M17xSFE4Pjh7Nki0
CHLA-255 M2\LeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvqU2QyKM7:TR?= MWS3NkBp Mn\5TY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJJRwKDJn NGPRTm4yPzZ6OU[4OC=>
SK-N-AS NVLxXmlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XlXFEh|ryP M2HjPVczKGh? M2rvfmlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyBzMDW= M3TWR|E4Pjh7Nki0
NB-1691 MUfGeY5kfGmxbjDBd5NigQ>? NUnH[Gt1OTBibl2= NW\xSJc{OjRiaB?= NYG0WWFWW2mpbnnmbYNidnSueTDy[YR2[2W|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\Q>? NIfoTnYyPzZ6OU[4OC=>
CHLA-255 NFnHdWtHfW6ldHnvckBCe3OjeR?= M4TMPFExKG6P NWjDPJlZOjRiaB?= MoKwUY9l\XO2bImgdoVlfWOnczDj[YxteyCrbjD0bIUhTzBxR{GgdIhie2V? MkDiNVc3QDl4OES=
RPMI 8226 MVzGeY5kfGmxbjDBd5NigQ>? MVuyNEBvVQ>? NUjVUVlRQCCq M3n3bXNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 M2OzXlE6PDN4MEWw
MM.1S MXjGeY5kfGmxbjDBd5NigQ>? MnPPNlAhdk1? NV\4XpBDQCCq NFOwTGlUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? M3X1bFE6PDN4MEWw
U266 NYr0WJV{TnWwY4Tpc44hSXO|YYm= Mo\JNlAhdk1? NIHqcHg5KGh? NFy1W2pUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? Mn7sNVk1OzZyNUC=
OPM1 MVzGeY5kfGmxbjDBd5NigQ>? MUSyNEBvVQ>? M4rDfFghcA>? MlvYV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> NYDDOIhiOTl2M{[wOVA>
INA6 M4T4OmZ2dmO2aX;uJGF{e2G7 MUKyNEBvVQ>? NWXNSJF1QCCq NWHlTXZnW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? NIrqSlcyQTR|NkC1NC=>
OPM2 M3rOfGZ2dmO2aX;uJGF{e2G7 MXWyNEBvVQ>? Mmn3PEBp M3TRWnNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 MYqxPVQ{PjB3MB?=
RPMI 8226 MlvTSpVv[3Srb36gRZN{[Xl? MUCyNEBvVQ>? MYO4JIg> NX\ucIhSUW6mdXPld{BFVkFic4nueIhme2m| MlLlNVk1OzZyNUC=
BaF/3 NGDhPXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfJPJAyODBibl2= M37BTlQ5KGh? NYLq[m5wUUN3ME22MlIhdk1? NXG1bGpjOjB|MEW2PVI>
BaF/3-p210 NFKyRnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX64OlZ1OTByIH7N NXHiSZpmPDhiaB?= NGDIe2ZKSzVyPUSuO{BvVQ>? MV:yNFMxPTZ7Mh?=
TCC-S NGHYNIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTyNVAxKG6P NEfIfFA1QCCq MUTJR|UxRTJwODDuUS=> NVTBcVFVOjB|MEW2PVI>
BaF/3 M{HIOmZ2dmO2aX;uJGF{e2G7 NVTIdHJJPiCwTR?= M1;sWVQ5KGh? M{KyT2lv\HWlZYOgZUBoemWjdDDHNUBk\WyuLXP5Z4xmKGG{cnXzeC=> NFTLTpIzODNyNU[5Ni=>
BaF/3-p210 M4Pz[2Z2dmO2aX;uJGF{e2G7 MXG2JI5O MmnjOFghcA>? MYrJcoR2[2W|IHGgd4xq\2i2IFexJINmdGxvY4njcIUh[XK{ZYP0 MmW0NlA{ODV4OUK=
BaF/3-p210 M4njfmZ2dmO2aX;uJGF{e2G7 MkXPOkBvVQ>? MWeyOEBp MXXS[YR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gZY5lKHSqZTDhZ5Rqfmm2eTDv[kBT[g>? MYeyNFMxPTZ7Mh?=
Raji M3q0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY[xJO69VQ>? M3jmfVI1KGh? M{DLdXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NGDUeIUzOTF5MEm4PC=>
LCL-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoSwNUDPxE1? NX7UfZdsOjRiaB?= MmDQVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi NH7kTGszOTF5MEm4PC=>
LCL-2 NX[0U4pDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUOxJO69VQ>? M4TTPVI1KGh? M2\KNXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NYTsfYxHOjFzN{C5PFg>
BJAB NWradnZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHqyZmUyKM7:TR?= M4n1fVI1KGh? MVnS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MX6yNVE4ODl6OB?=
SNT-13 NWHrUGV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnv6NUDPxE1? MkH6NlQhcA>? MnLyVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi NFy0[nEzOTF5MEm4PC=>
SNT-16 NVTQSlBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPH[YttOSEQvF2= NVfJUHljOjRiaB?= MofxVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi Mkn6NlEyPzB7OEi=
Jurkat NHXxOpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETY[nMyKM7:TR?= NFvjNI0zPCCq M1rHR3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NXPLSXM5OjFzN{C5PFg>
KAI-3 M2nXZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHNTos2OSEQvF2= MY[yOEBp NYP2TVY5WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NFn3TnczOTF5MEm4PC=>
SNK-6 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TMXVEh|ryP NUTWW3BEOjRiaB?= M4nCUnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NIDtT3YzOTF5MEm4PC=>
KHYG-1 NUDWT3JMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYexJO69VQ>? NYS5V2x4OjRiaB?= MWXS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? M4XCOlIyOTdyOUi4
SNT-16 MW\BdI9xfG:|aYOgRZN{[Xl? NFfwcYMyKM7:TR?= NIDqPVk3KGh? NUf0eYVnUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MYOyNVE4ODl6OB?=
Jurkat NX36XpFGSXCxcITvd4l{KEG|c3H5 M33ofFEh|ryP NIPkdJA3KGh? MUTJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NVnMT4o{OjFzN{C5PFg>
KAI-3 NVj5TolqSXCxcITvd4l{KEG|c3H5 NWjJTlBPOSEQvF2= M3T2dFYhcA>? NFPpSpdKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NHK5c|IzOTF5MEm4PC=>
KHYG-1 MnjzRZBweHSxc3nzJGF{e2G7 MofhNUDPxE1? M1rU[lYhcA>? NWrhOIxuUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= Mn2xNlEyPzB7OEi=
SNT-13 NVXPdoRySW62aY\pdoFtKEG|c3H5 MX6xJO69VQ>? Mny1NlQhcA>? NXTlV5REUW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY M1PSVlIyOTdyOUi4
SNT-16 NEHidXdCdnSrdnnyZYwhSXO|YYm= NGn6UVAyKM7:TR?= NVi5NW5nOjRiaB?= NF3jcHNKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? NHzUUJgzOTF5MEm4PC=>
KAI-3 NV\XZ3FFSW62aY\pdoFtKEG|c3H5 M2rMflEh|ryP MnjsNlQhcA>? NXXrWpFjUW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY MnHjNlEyPzB7OEi=
SNK-6 MYHBcpRqfmm{YXygRZN{[Xl? NELaV4YyKM7:TR?= NHHsdWEzPCCq NHzDVlRKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? MVmyNVE4ODl6OB?=
RAW 264.7 NHn3PXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jSNlExOCCwTR?= NVu0fmtQPDhiaB?= NIW1b|RT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MXiyNlQzPzF3NB?=
A375 MWHBdI9xfG:|aYOgRZN{[Xl? NEG4RnIyOCCwTR?= MnnMNlQhcA>? MUjJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NV;hZZFTOjNyN{mwPFM>
BLM MXLBdI9xfG:|aYOgRZN{[Xl? NYDhOIZQOTBibl2= MY[yOEBp NH\FTJlKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MUeyN|A4QTB6Mx?=
A375 MVrBeZRweGijZ4mgRZN{[Xl? MkKyNVAhdk1? MnfjNVIhcA>? NH;GfIRKdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> NXLWdItsOjNyN{mwPFM>
BLM MmXaRZV1d3CqYXf5JGF{e2G7 MoPkNVAhdk1? M1Sz[FEzKGh? NI\XPVlKdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> M1rtXFI{ODd7MEiz
H1299 Ml7JRZBweHSxc3nzJGF{e2G7 M33YO|gxKG6P MWeyOEBp MVLEUXNQ M2G4SnNmdnOrdHn6[ZMhVlOFTFOgZ4VtdHNidH:gUXNENWSncnn2[YQhcUN7LXnu[JVk\WRiYYDvdJRwe2m| M3;pcFI2OzJ|Nkmz
Hut-78 MWfGeY5kfGmxbjDBd5NigQ>? NEjL[mIyODBibl2= M1;J[|I1KGh? Ml3xSG1UVw>? M1nvTWRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTBiZYjwdoV{e2mxbh?= MXuyOVY5OTN|NR?=
H9 NYO3O3NYTnWwY4Tpc44hSXO|YYm= M4rSVlExOCCwTR?= M3PvcFI1KGh? NVPjOpFFTE2VTx?= MWnEc5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVEyKGW6cILld5Nqd25? M3TZ[lI2PjhzM{O1
HH NW\k[ml3TnWwY4Tpc44hSXO|YYm= MVOxNFAhdk1? NHPSc|EzPCCq MXPEUXNQ MlHz[I94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOiCneIDy[ZN{cW:w MUCyOVY5OTN|NR?=
Hut-78 MlixUYloemG2aX;uJGF{e2G7 NYfxVYtLOTByIH7N NF7B[o4zPCCq MYLEUXNQ MUnS[YR2[2W|IHPlcIwhdWmpcnH0bY9vKGK7IEiw5qCUQTBn NXS2elFrOjV4OEGzN|U>
HH NIjTVW9OcWe{YYTpc44hSXO|YYm= NXPrWVQzOTByIH7N NUnhNWlFOjRiaB?= NYDVXmJiTE2VTx?= MXXS[YR2[2W|IHPlcIwhdWmpcnH0bY9vKGK7IEiw5qCUQTFn NIjFe4wzPTZ6MUOzOS=>
U937 NFTaVG9HfW6ldHnvckBCe3OjeR?= NXHYWFJ6OTByIH7N NXPoe4lYPiCq MVXJcoR2[2W|IFnMMVgh\XiycnXzd4lwdiCrbjDMVHMue3SrbYXsZZRm\CCXOUO3JI1i[3KxcHjh[4V{ M3\EU|I2PzlzNEe3
human PBMC M3LLPGZ2dmO2aX;uJGF{e2G7 MXqxNFAhdk1? MYmyOEBp MnLJTY5lfWOnczDJUE05KHKnbHXhd4U> MkX4NlU4QTF2N{e=
ES6 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXmNWs5UUN3ME2wMlAxOjFibl2= NYruSZB2W0GQR1XS
SK-UT-1 NGnOeWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnQeJpSUUN3ME2wMlE3OyCwTR?= NV7PPGdMW0GQR1XS
SH-4 M4TqRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnG3TWM2OD1yLkG3N{BvVQ>? M1juOHNCVkeHUh?=
TE-9 NXHTdmpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMUiyJI5O MXvTRW5ITVJ?
A253 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPsUZN2UUN3ME2wMlIxQCCwTR?= MVTTRW5ITVJ?
no-10 NG[2PJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUO1RZRRUUN3ME2wMlIyKG6P M1X0W3NCVkeHUh?=
MMAC-SF MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojFTWM2OD1yLkKxOkBvVQ>? NXPRb5FvW0GQR1XS
A101D NV;BXHltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\DbYdPUUN3ME2wMlIzPSCwTR?= NF7qbm9USU6JRWK=
NTERA-S-cl-D1 M3HsTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TLb2lEPTB;MD6yOFMhdk1? MWrTRW5ITVJ?
8-MG-BA MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3MSHlPUUN3ME2wMlI2KG6P M3e1VnNCVkeHUh?=
KNS-42 M1rvPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljzTWM2OD1yLkK1PEBvVQ>? Mln3V2FPT0WU
LXF-289 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LkS2lEPTB;MD6yOlkhdk1? MlPqV2FPT0WU
OVCAR-4 NU\TOG8yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULmU5FSUUN3ME2wMlI5QSCwTR?= Mn3pV2FPT0WU
LOUCY NVq3NnJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTF[mtKSzVyPUCuNlk{KG6P NXSx[|ViW0GQR1XS
BB65-RCC MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXUTWM2OD1yLkOwOEBvVQ>? NF7Z[YVUSU6JRWK=
D-542MG NF3wd3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwM{K5JI5O M2KwPHNCVkeHUh?=
ONS-76 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\USlRXUUN3ME2wMlM{KG6P M1S4[HNCVkeHUh?=
BB30-HNC MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX61foNEUUN3ME2wMlM{PSCwTR?= MWfTRW5ITVJ?
KS-1 NULyNIo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTyTWM2OD1yLkO0JI5O NVrSeJNtW0GQR1XS
A388 Mn7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLvTWM2OD1yLkO1OkBvVQ>? NHi0XGJUSU6JRWK=
ES8 M3:0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml61TWM2OD1yLkSgcm0> MoPBV2FPT0WU
MZ2-MEL NVLPdYVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwNEC3JI5O MYXTRW5ITVJ?
HCC2998 NGDIVldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYf1WIpoUUN3ME2wMlQyOiCwTR?= NEfuO|FUSU6JRWK=
D-247MG NFy3VldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;kRmlEPTB;MD60NVMhdk1? NIjnOlZUSU6JRWK=
ACN Mm[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fuXmlEPTB;MD60NVchdk1? NXr6e29mW0GQR1XS
LB2518-MEL NVfqWYNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXJfmh3UUN3ME2wMlQzPSCwTR?= M4rNOnNCVkeHUh?=
ES1 M1X6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnm1TWM2OD1yLkSzJI5O MXXTRW5ITVJ?
HCE-T M4DRUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jRRWlEPTB;MD60N|khdk1? MYrTRW5ITVJ?
OS-RC-2 NYrvXW9LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTBwNESgcm0> M4rCNHNCVkeHUh?=
MFH-ino MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfET3lKSzVyPUCuOFQ{KG6P NGLTdlhUSU6JRWK=
OCUB-M NUThdJhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfGTWM2OD1yLkS0O{BvVQ>? NEjMc3BUSU6JRWK=
CP66-MEL NF;WT3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwNEezJI5O Mly4V2FPT0WU
LB771-HNC NH3jNmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDFTWM2OD1yLkS3OEBvVQ>? NUnFZVM3W0GQR1XS
DSH1 NIjPcYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwNEigcm0> Mnu4V2FPT0WU
HUTU-80 NWLVPY9qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwNUOzJI5O NGjCN4dUSU6JRWK=
CESS M2rYcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwNUO4JI5O NYX5RZh6W0GQR1XS
NCI-H747 M4PIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7OO2dlUUN3ME2wMlU{QSCwTR?= NFLlN3hUSU6JRWK=
HT-144 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1m1[2lEPTB;MD61O|Yhdk1? NVTxXldtW0GQR1XS
COLO-829 NVXae|E6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLHTWM2OD1yLk[xOEBvVQ>? NIDmfYRUSU6JRWK=
A4-Fuk MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPC[GNKSzVyPUCuOlI{KG6P NU[zcHNYW0GQR1XS
GI-ME-N MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fXW2lEPTB;MD62N|Qhdk1? NIn6PVJUSU6JRWK=
LB831-BLC MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnoTWM2OD1yLk[0NUBvVQ>? MoP3V2FPT0WU
HOP-62 MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTBwNkS3JI5O MlP1V2FPT0WU
BB49-HNC NYO1[W1ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwNkWyJI5O MWPTRW5ITVJ?
D-336MG M1LsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTBdIJKSzVyPUCuOlU4KG6P NWPibnBGW0GQR1XS
TK10 MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4j6fWlEPTB;MD62O|khdk1? M{Tr[3NCVkeHUh?=
Ramos-2G6-4C10 MmXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1H2cmlEPTB;MD62PVMhdk1? NXHWc29KW0GQR1XS
LB373-MEL-D Mn\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nyXWlEPTB;MD63JI5O M4HyXHNCVkeHUh?=
SF126 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYn0Sm9QUUN3ME2wMlcxOSCwTR?= NUPlSVlLW0GQR1XS
UACC-257 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnre5FrUUN3ME2wMlcyKG6P MWrTRW5ITVJ?
KINGS-1 NF;IeYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXLNFBKSzVyPUCuO|IzKG6P NXLsb5NMW0GQR1XS
LS-513 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwN{O5JI5O MkfFV2FPT0WU
GI-1 NYq1NIFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPyTWM2OD1yLke2OEBvVQ>? NF75[HJUSU6JRWK=
ES7 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzCRYRmUUN3ME2wMlc3PiCwTR?= MYXTRW5ITVJ?
LB2241-RCC Ml3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwOEC0JI5O Ml7IV2FPT0WU
D-263MG NIDhVWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fsWWlEPTB;MD64NFchdk1? MonkV2FPT0WU
SW684 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwOEKxJI5O MUDTRW5ITVJ?
ML-2 MkP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoKyTWM2OD1yLkiyNUBvVQ>? MWXTRW5ITVJ?
SK-LMS-1 NYK0PVJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV35[49DUUN3ME2wMlg2PCCwTR?= NH\3TZBUSU6JRWK=
TE-5 M{P2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF6zZotKSzVyPUCuPFY2KG6P M3zmbHNCVkeHUh?=
QIMR-WIL NVvRSnJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHWTotKSzVyPUCuPFg6KG6P NFTSU4JUSU6JRWK=
NCI-H1355 NULzTnpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmD1TWM2OD1yLki5OUBvVQ>? MlHFV2FPT0WU
SNB75 MoXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7vTnF7UUN3ME2wMlkyOiCwTR?= NUjxZZFVW0GQR1XS
RXF393 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnr2TWM2OD1yLkmxOEBvVQ>? MoX6V2FPT0WU
IST-MEL1 NF;XVopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjYfpptUUN3ME2wMlkyPyCwTR?= M3;wS3NCVkeHUh?=
SF268 NVrFbllKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEe3OmxKSzVyPUCuPVI{KG6P NILwVIxUSU6JRWK=
KALS-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXHWpU2UUN3ME2wMlkzPSCwTR?= MmLQV2FPT0WU
HC-1 NIjXV3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwOUe1JI5O MWXTRW5ITVJ?
SW872 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPicW45UUN3ME2wMlk6PiCwTR?= NIfFXJNUSU6JRWK=
PSN1 M1;xR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLkTotKSzVyPUGuNFEhdk1? NXTiRnVuW0GQR1XS
TE-1 NXjQ[WNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPVVoNKSzVyPUGuNFMhdk1? MVrTRW5ITVJ?
TE-10 NGDOZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTFwMEOgcm0> NIK3cFFUSU6JRWK=
RKO MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIm2RZRKSzVyPUGuNFYhdk1? MVrTRW5ITVJ?
LC-2-ad MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX[wbY9TUUN3ME2xMlA5KG6P NV\IOVZkW0GQR1XS
SK-MM-2 MlTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTFwMEmgcm0> M1OzRXNCVkeHUh?=
VA-ES-BJ M3XkcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXmzbIRsUUN3ME2xMlA6KG6P MXrTRW5ITVJ?
MZ7-mel Mnz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3KWmNKSzVyPUGuNFkhdk1? MUfTRW5ITVJ?
D-392MG Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX35T3ppUUN3ME2xMlEhdk1? MX;TRW5ITVJ?
CCRF-CEM MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\HUGdKSzVyPUGuNVMhdk1? MYjTRW5ITVJ?
EM-2 NV;HTpc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTFwMU[gcm0> MXjTRW5ITVJ?
HAL-01 NHnPWHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MomyTWM2OD1zLkG4JI5O NI\4XG9USU6JRWK=
TE-8 M{P4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3ONo1KSzVyPUGuNVkhdk1? MW\TRW5ITVJ?
NCI-H1882 NEnpVWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTFwMjDuUS=> MkSxV2FPT0WU
Daudi M372emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUX1c|RvUUN3ME2xMlIzKG6P MlH4V2FPT0WU
BL-41 NUHvdnhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjXTWM2OD1zLkK1JI5O M1XMVnNCVkeHUh?=
SR MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGP3[W5KSzVyPUGuNlUhdk1? NHnHRoZUSU6JRWK=
KM12 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTFwMkegcm0> NGS5cGZUSU6JRWK=
K5 MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGS3fWxKSzVyPUGuNlghdk1? NEfqbotUSU6JRWK=
A3-KAW Mn\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3q2RWlEPTB;MT6yPEBvVQ>? MUPTRW5ITVJ?
CMK MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXOTWM2OD1zLkK5JI5O MlXJV2FPT0WU
Calu-6 M3vQNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTFwMkmgcm0> MXnTRW5ITVJ?
IST-SL2 M{\rZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTFwM{Ggcm0> NHnoNXpUSU6JRWK=
OPM-2 NV3ldpZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPDV2dKSzVyPUGuN|Mhdk1? Ml7YV2FPT0WU
DU-4475 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTFwM{[gcm0> M{DzfXNCVkeHUh?=
ECC12 NYHjO2pxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTFwM{egcm0> NHzl[IhUSU6JRWK=
L-540 NYrkbnh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTFwM{egcm0> M1HxcnNCVkeHUh?=
CAS-1 Mnq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2WwSWlEPTB;MT6zO{BvVQ>? NYLmOIVTW0GQR1XS
PF-382 M1jo[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1L6[WlEPTB;MT60O{BvVQ>? MWjTRW5ITVJ?
LS-411N M2H3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zmR2lEPTB;MT61N{BvVQ>? NGPjVIFUSU6JRWK=
NCI-H69 NHm1[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHiTWM2OD1zLkW0JI5O M{fP[HNCVkeHUh?=
NB12 M4Xwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7NTWM2OD1zLkW2JI5O NUHCflZOW0GQR1XS
HEL NYfCeIVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPteIJKSzVyPUGuOlEhdk1? MWTTRW5ITVJ?
GCIY M4OyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkf6TWM2OD1zLk[yJI5O NWXJclRkW0GQR1XS
EHEB NWG4OWdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDSTWM2OD1zLk[3JI5O MVrTRW5ITVJ?
TGBC1TKB NELKNWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTFwN{Ggcm0> MVnTRW5ITVJ?
KURAMOCHI NU\ORlFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnG3TWM2OD1zLkeyJI5O NFziOXhUSU6JRWK=
U-266 NHjZUVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTFwN{[gcm0> Ml\RV2FPT0WU
LC4-1 NYTWSWNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTFwN{mgcm0> NGPMUIVUSU6JRWK=
NCI-H2126 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Pa[GlEPTB;MT64JI5O MYLTRW5ITVJ?
NCI-H1092 MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3niWWlEPTB;MT64JI5O M4izOHNCVkeHUh?=
GB-1 NFThWWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHWyVlVKSzVyPUGuPFEhdk1? NWrxR5hoW0GQR1XS
MV-4-11 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{K1d2lEPTB;MT64NkBvVQ>? M4XSb3NCVkeHUh?=
Becker M3nlSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrh[2g6UUN3ME2xMlg{KG6P M3rRZnNCVkeHUh?=
MPP-89 Mn3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXRTWM2OD1zLki5JI5O NULobGdwW0GQR1XS
BE-13 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTFwOUOgcm0> MWnTRW5ITVJ?
697 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTFwOUmgcm0> NHXXWWxUSU6JRWK=
NKM-1 NYPycYRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jZe2lEPTB;MjDuUS=> NXnZV|RvW0GQR1XS
NB13 M3TUOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJibl2= MUTTRW5ITVJ?
LS-123 NXfJT4ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TEdWlEPTB;Mj6wNkBvVQ>? MlXXV2FPT0WU
NB17 NVOzeVBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LzcWlEPTB;Mj6wOEBvVQ>? M{\Dc3NCVkeHUh?=
LAN-6 MmHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInmSZVKSzVyPUKuNFUhdk1? M{jLdXNCVkeHUh?=
EW-24 Mk[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknmTWM2OD1{LkC4JI5O MkXhV2FPT0WU
NOS-1 NETTWGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTtTWM2OD1{LkGxJI5O MVTTRW5ITVJ?
BL-70 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUT1U4Y{UUN3ME2yMlEzKG6P NYqy[VdPW0GQR1XS
GT3TKB NHv4em9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJwMUKgcm0> NWjB[WF1W0GQR1XS
HH NHjDbVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PGWWlEPTB;Mj6xN{BvVQ>? MYXTRW5ITVJ?
KE-37 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDDTWM2OD1{LkGzJI5O M1T5[XNCVkeHUh?=
MOLT-4 M1vxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1juNGlEPTB;Mj6xN{BvVQ>? MmWxV2FPT0WU
EKVX Mon4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Twe2lEPTB;Mj6xOEBvVQ>? MonQV2FPT0WU
KGN Mo\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTJwMUWgcm0> MULTRW5ITVJ?
ES4 M1TpRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoW4TWM2OD1{LkG2JI5O NUXz[pozW0GQR1XS
SJSA-1 NXfnS5E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWP4SnQ3UUN3ME2yMlIyKG6P NHnrWGVUSU6JRWK=
KMOE-2 NVy4cpFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTlTWM2OD1{LkKzJI5O MnXnV2FPT0WU
NB5 M4TJR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjMeHlOUUN3ME2yMlI4KG6P MnfHV2FPT0WU
BC-1 NFy3bYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjMTWM2OD1{LkOxJI5O MYfTRW5ITVJ?
NB10 MmXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;BTWM2OD1{LkOyJI5O MWXTRW5ITVJ?
RPMI-8226 M2i5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGm5[45KSzVyPUKuN|Uhdk1? Mn3QV2FPT0WU
SCC-3 MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\GTWM2OD1{LkO3JI5O M2eyNnNCVkeHUh?=
ARH-77 NGKzbVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\zU2lEPTB;Mj6zPEBvVQ>? MUnTRW5ITVJ?
NCI-H748 NInE[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTJwM{mgcm0> NWTSe4cxW0GQR1XS
KU812 NYfYVVVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEW2VoVKSzVyPUKuOFIhdk1? NYHtXmQ2W0GQR1XS
NCI-H64 NEPVbHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTHWZFpUUN3ME2yMlQ1KG6P M{jMNXNCVkeHUh?=
NB69 NUTuXphrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\4bmlEPTB;Mj60OkBvVQ>? NF7DUIxUSU6JRWK=
KNS-81-FD Mnf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mke1TWM2OD1{LkS4JI5O NWL1cVI5W0GQR1XS
LB1047-RCC NFjje5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnywTWM2OD1{LkW3JI5O MV\TRW5ITVJ?
EB-3 Mkj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoflTWM2OD1{Lk[2JI5O NWK0cY1TW0GQR1XS
Mo-T M{LySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHpTHlWUUN3ME2yMlc1KG6P MV;TRW5ITVJ?
EW-16 NGPj[nlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTJwN{Wgcm0> Ml;wV2FPT0WU
CTV-1 NFrFRppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrJUI5RUUN3ME2yMlghdk1? Mmf3V2FPT0WU
ETK-1 MmPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJwOESgcm0> NUf0e49LW0GQR1XS
C2BBe1 NH3T[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPaTWM2OD1{Lki5JI5O NHe4WJRUSU6JRWK=
MOLT-16 NEDwfGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33pWmlEPTB;Mj64PUBvVQ>? MYfTRW5ITVJ?
SW954 Mn7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlS3TWM2OD1{Lkmgcm0> NEHuO3JUSU6JRWK=
HT M1v2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnziTWM2OD1|LkCyJI5O NIT6SFlUSU6JRWK=
KARPAS-299 NEnV[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jqUWlEPTB;Mz6wOkBvVQ>? Ml\RV2FPT0WU
MONO-MAC-6 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDsTWM2OD1|LkGgcm0> Moi4V2FPT0WU
CGTH-W-1 MljWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1v3d2lEPTB;Mz6xJI5O MkjHV2FPT0WU
SK-PN-DW NWDkVHRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFK3dY9KSzVyPUOuNVQhdk1? M3nJOnNCVkeHUh?=
CW-2 NGqwXY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGe5WYFKSzVyPUOuNlEhdk1? MYPTRW5ITVJ?
SK-N-DZ NEf4bmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDXPXlwUUN3ME2zMlI3KG6P NHnBUJlUSU6JRWK=
NEC8 MkHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTNwM{Wgcm0> M{GyWnNCVkeHUh?=
LB996-RCC NVvpb3hYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvyXFBKSzVyPUOuOEBvVQ>? M4HLd3NCVkeHUh?=
DB M2HKWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLCSZpKSzVyPUOuOFEhdk1? Mnj3V2FPT0WU
TE-15 NVvGOWpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTNwNEOgcm0> M2HtWXNCVkeHUh?=
COR-L88 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTNwNEegcm0> M1zKe3NCVkeHUh?=
LAMA-84 NUjOSo9iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\pTmlEPTB;Mz60PUBvVQ>? NF70bnFUSU6JRWK=
MEG-01 NWrwTGhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTNwNEmgcm0> NGrjZZBUSU6JRWK=
LOXIMVI NID0NWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYP0fmVSUUN3ME2zMlUhdk1? MYjTRW5ITVJ?
RPMI-8402 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jw[mlEPTB;Mz61JI5O MlvJV2FPT0WU
KARPAS-45 MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHUTWM2OD1|LkW0JI5O NETsO2xUSU6JRWK=
HCC1187 MmDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXzTWM2OD1|LkW0JI5O MUfTRW5ITVJ?
MZ1-PC NVPEVppKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfDfW5KSzVyPUOuOVQhdk1? NVj3bWpwW0GQR1XS
no-11 NVLSRlNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vPVWlEPTB;Mz61OUBvVQ>? M{H1cXNCVkeHUh?=
EVSA-T NHva[pFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTNwNjDuUS=> NVvTV|VLW0GQR1XS
DJM-1 M2TqSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\YbGFXUUN3ME2zMlY{KG6P MXfTRW5ITVJ?
COLO-684 M3\QSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTNwNk[gcm0> NFfFSIxUSU6JRWK=
NMC-G1 M{n3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTNwNkigcm0> MUTTRW5ITVJ?
LC-1F NVfP[mZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXX1NnYyUUN3ME2zMlc1KG6P NIDhXHNUSU6JRWK=
RL95-2 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zuXmlEPTB;Mz63PUBvVQ>? NWmwVmQ2W0GQR1XS
COLO-320-HSR M1XBdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXmVmJ5UUN3ME2zMlkzKG6P MkLUV2FPT0WU
RCC10RGB MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHWNlNKSzVyPUOuPVMhdk1? Mli3V2FPT0WU
HD-MY-Z MorjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3TTWM2OD1|LkmzJI5O MXHTRW5ITVJ?
NCI-H2141 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTRwMEWgcm0> NHjESlZUSU6JRWK=
K-562 M3LjWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\ZbVNFUUN3ME20MlEzKG6P NHXv[4JUSU6JRWK=
NCI-H1648 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTYRoNRUUN3ME20MlE{KG6P MnjkV2FPT0WU
OMC-1 Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rHbGlEPTB;ND6xPEBvVQ>? MWnTRW5ITVJ?
LB647-SCLC NUH5fWhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTRwMkKgcm0> MWrTRW5ITVJ?
TE-12 NYPwcHZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjFS3VUUUN3ME20MlI2KG6P NUTwdFZCW0GQR1XS
NOMO-1 NXq2U|Z4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTRwM{Ogcm0> M{\zZnNCVkeHUh?=
Raji M17SNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYC1OHJDUUN3ME20MlQ3KG6P MUjTRW5ITVJ?
NALM-6 NHXYVm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHycnRKSzVyPUSuOFkhdk1? NGXmfVRUSU6JRWK=
HL-60 Mnf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvUV41YUUN3ME20MlY4KG6P Mmi2V2FPT0WU
IST-SL1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfzSIZKSzVyPUSuOlghdk1? NW\FPYZtW0GQR1XS
MHH-PREB-1 MkDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDNTWM2OD12Lki2JI5O NGXEbWtUSU6JRWK=
MHH-NB-11 M1LDUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;IdlZKSzVyPUSuPVEhdk1? MmLTV2FPT0WU
JiyoyeP-2003 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHpTWM2OD13IH7N MVrTRW5ITVJ?
SBC-1 MofBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTVwMEGgcm0> NGTKZmJUSU6JRWK=
CHP-126 M3q5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\CZ2lEPTB;NT6wOkBvVQ>? NYXhfGViW0GQR1XS
LU-139 NWnpV3FkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlz6TWM2OD13LkGzJI5O Mn6xV2FPT0WU
NCI-SNU-5 M1TRVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTVwMUegcm0> M33R[3NCVkeHUh?=
SW962 MoPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnqTWM2OD13LkKxJI5O NEjkUGZUSU6JRWK=
EW-1 NFfE[lNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjhPG1bUUN3ME21MlMyKG6P NXXMNmZbW0GQR1XS
NCI-H1417 NG\HfGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWH6Nm9LUUN3ME21MlUyKG6P NF7OeVVUSU6JRWK=
LU-65 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVL5[mxuUUN3ME21Mlg1KG6P M1fnNXNCVkeHUh?=
D-502MG NVXXeoJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITubFhKSzVyPU[uN|chdk1? NELXeFVUSU6JRWK=
BC-3 NGDIWnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXPSoVKSzVyPU[uOlEhdk1? NF35WYtUSU6JRWK=
GDM-1 M1K0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnWxTWM2OD14Lke3JI5O NIfHVmFUSU6JRWK=
NCI-H2196 NITNWIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml73TWM2OD14Lkigcm0> M3r0PHNCVkeHUh?=
NB1 NIWz[|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHLT4FKSzVyPU[uPFghdk1? Mn;YV2FPT0WU
NCI-H345 NG\JXmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfaTWM2OD15LkKgcm0> Mm\BV2FPT0WU
SU-DHL-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{ezW2lEPTB;Nz6yOEBvVQ>? MoX5V2FPT0WU
JVM-2 Mn[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HK[mlEPTB;Nz6yPEBvVQ>? MVzTRW5ITVJ?
LU-134-A NEDXRpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXITWM2OD15LkO5JI5O MWTTRW5ITVJ?
NCI-H1694 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHxTnhKSzVyPUeuOVghdk1? NG\iPHNUSU6JRWK=
NCI-SNU-16 NI\0R|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nNV2lEPTB;Nz62OUBvVQ>? MoHYV2FPT0WU
L-363 MlXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTdwNzDuUS=> M2OwNXNCVkeHUh?=
KG-1 M{j4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjTToxKSzVyPUeuPVQhdk1? NXHZNYY3W0GQR1XS
MN-60 MlKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWH0clQyUUN3ME24MlE1KG6P MoXGV2FPT0WU
NB6 NEXvbo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILPRnFKSzVyPUiuOFghdk1? NFPi[oRUSU6JRWK=
MLMA NFfEZ|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;FflgyUUN3ME24Mlg2KG6P NHjkWVNUSU6JRWK=
ATN-1 NIWwSFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTMTWM2OD16Lki5JI5O NEHKW4pUSU6JRWK=
SK-NEP-1 MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\BU2lEPTB;OT6wNUBvVQ>? MYDTRW5ITVJ?
DMS-114 M3nLUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFP0emtKSzVyPUmuOlIhdk1? NWLGS|hvW0GQR1XS
CTB-1 NHf6UYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTlwNkegcm0> MXXTRW5ITVJ?
NCI-H2081 MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\qTWM2OD1zMD6wPUBvVQ>? NFrvSXBUSU6JRWK=
ES5 MoHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{G2NGlEPTB;MUCuN|ghdk1? MoHCV2FPT0WU
HCC1599 M2LjU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fCe2lEPTB;MUGuPVEhdk1? MUnTRW5ITVJ?
NCI-H23 Ml3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTsSGxEUUN3ME2xNk4yOiCwTR?= MoPIV2FPT0WU
NCI-H1581 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTVTWM2OD1zMj6yPEBvVQ>? NHntOFNUSU6JRWK=
JVM-3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHX0[GJKSzVyPUGyMlk6KG6P MVLTRW5ITVJ?
NCI-SNU-1 M4LYfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTF|LkG5JI5O NIXUbWNUSU6JRWK=
NB7 MoTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGL2NIVKSzVyPUG1MlkzKG6P MmnJV2FPT0WU
JAR NGTRTpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{P4emlEPTB;MU[uNVMhdk1? MlLVV2FPT0WU
TGW NEXjV|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zVOmlEPTB;MU[uOFghdk1? NXfuSYpsW0GQR1XS
U-87-MG MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3yTWM2OD1zNj63OkBvVQ>? NGXiRYxUSU6JRWK=
NCI-H1436 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnme5RKSzVyPUG3MlAyKG6P M2rvenNCVkeHUh?=
GOTO NGq3VmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnncJNtUUN3ME2xO{4xPiCwTR?= M1HNb3NCVkeHUh?=
COLO-800 NXP5TW5WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\BTWM2OD1zNz62OEBvVQ>? NV61WZBrW0GQR1XS
MFM-223 MlfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LCOmlEPTB;MUeuPVEhdk1? NHLpOVFUSU6JRWK=
EW-18 M2rodGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfkTWM2OD1zNz65OkBvVQ>? MVjTRW5ITVJ?
NB14 NXW4[Yl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTF5Lkm4JI5O NWj5eWVtW0GQR1XS
EB2 NFzvVmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvpTWM2OD1zOD6wPEBvVQ>? NETMZZVUSU6JRWK=
EoL-1- NWm1V5BJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HJVGlEPTB;MUiuN|Ehdk1? NEX6TlJUSU6JRWK=
NCCIT NF3LZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1H6bmlEPTB;MUiuN|Yhdk1? M4G2[HNCVkeHUh?=
DG-75 MmC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjtTWM2OD1zOD62NUBvVQ>? NVLuW4hTW0GQR1XS
HCC2218 NXfPWJN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTF7LkWgcm0> NVTiO3o3W0GQR1XS
TE-6 NHKxTJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[5TWM2OD1{MD6wPEBvVQ>? MlywV2FPT0WU
SF539 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTJyLk[3JI5O NX[yU4w{W0GQR1XS
NCI-H446 NVWwWlh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nu[WlEPTB;MkGuNVghdk1? MVXTRW5ITVJ?
IST-MES1 M1q1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTJ{Lke3JI5O M3q3UnNCVkeHUh?=
NCI-H82 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWWzWWpKUUN3ME2yN{4xOiCwTR?= NYn5VY46W0GQR1XS
HCC2157 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJ|LkGzJI5O NVjJTVVjW0GQR1XS
EW-12 NVroXIJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTJ|LkG3JI5O M{XBO3NCVkeHUh?=
SIMA MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInIcFRKSzVyPUKzMlM5KG6P NEnpTJpUSU6JRWK=
DOHH-2 Mn\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4i2TGlEPTB;MkOuOFUhdk1? NVyyRmUxW0GQR1XS
IM-9 NUnPb2xLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nlWWlEPTB;MkOuOVQhdk1? NHHkWoVUSU6JRWK=
EC-GI-10 NHTEXZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XqeGlEPTB;MkSuNlMhdk1? NXrzPYxlW0GQR1XS
HDLM-2 MnXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEf4NZVKSzVyPUK0MlU1KG6P NWq3[JJTW0GQR1XS
LS-1034 NFTuWZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPVfpBKSzVyPUK1Mlc2KG6P NWDueZRTW0GQR1XS
REH NWXlUVV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rRUGlEPTB;Mk[uOFEhdk1? NXHoV4lCW0GQR1XS
LU-165 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7FZZB3UUN3ME2yOk44OiCwTR?= MkS1V2FPT0WU
NH-12 M3;wNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTJ5Lk[3JI5O M{nCS3NCVkeHUh?=
WSU-NHL NF3xZndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Pr[2lEPTB;MkiuN|khdk1? MUDTRW5ITVJ?
ECC4 NE\ZW3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2OwNmlEPTB;MkiuO|khdk1? NEG4OmZUSU6JRWK=
OCI-AML2 Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4r0VmlEPTB;MkmuOlkhdk1? MUTTRW5ITVJ?
EW-3 NELvWm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTNyLkW5JI5O M3q0V3NCVkeHUh?=
NCI-H526 M1i2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDTPHZKSzVyPUOyMlU1KG6P MVPTRW5ITVJ?
NCI-H719 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\hXHhKSzVyPUO0MlMyKG6P MkH6V2FPT0WU
KARPAS-422 MnHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTN3LkC0JI5O MljEV2FPT0WU
SK-MEL-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\6fmlEPTB;M{WuNVchdk1? M1rRS3NCVkeHUh?=
ES3 NYDrWIVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnsT2g5UUN3ME2zOU4yQSCwTR?= MnywV2FPT0WU
UACC-812 MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPDTWM2OD1|NT60OEBvVQ>? NEmzdVVUSU6JRWK=
C8166 NWnY[XJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M122VmlEPTB;M{WuO{BvVQ>? NYntO2RWW0GQR1XS
MDA-MB-134-VI M3TXZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTN3Lki3JI5O M1;mS3NCVkeHUh?=
D-283MED NF;nWJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHe5VFlKSzVyPUO3Mlc6KG6P M1vYWHNCVkeHUh?=
SHP-77 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTiRWc1UUN3ME2zPE4xOyCwTR?= NE\kVoRUSU6JRWK=
NCI-H2227 M1HCWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPndVJxUUN3ME20NE41QSCwTR?= MorxV2FPT0WU
SKM-1 M17zc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTR{Lk[zJI5O NHfrZ5pUSU6JRWK=
L-428 NWm4dohZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HjbmlEPTB;NEOuPFYhdk1? MlL2V2FPT0WU
RPMI-6666 NGezNlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTR3Lki5JI5O MYjTRW5ITVJ?
NCI-H716 MoO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHwTWM2OD12OD64NUBvVQ>? NHOze3ZUSU6JRWK=
DMS-79 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTVyLkexJI5O NGj6b3JUSU6JRWK=
RS4-11 NH3xeW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTFOmdVUUN3ME21NE45QCCwTR?= MUPTRW5ITVJ?
NCI-H720 MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTVzLkGxJI5O MYDTRW5ITVJ?
MC-CAR M3\w[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWqzfnFHUUN3ME21NU42OiCwTR?= MWPTRW5ITVJ?
TALL-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTV|LkmxJI5O MoXPV2FPT0WU
NCI-N87 NHW1bGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTV2LkG4JI5O NH3hUIRUSU6JRWK=
P30-OHK MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTV2Lk[xJI5O M2ezc3NCVkeHUh?=
LP-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTZzLkK4JI5O NUXlOI1GW0GQR1XS
YT MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjyTWM2OD14MT64JI5O MVLTRW5ITVJ?
MRK-nu-1 NXjPOokzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXucGlKSzVyPU[xMlgzKG6P MX7TRW5ITVJ?
BT-474 NHTlU2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jFe2lEPTB;NkWgcm0> M1fHZnNCVkeHUh?=
NCI-H322M MmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvyOmJKSzVyPU[2MlEyKG6P MonBV2FPT0WU
NCI-H128 NEXHO2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF6xfHJKSzVyPUe0Mlc4KG6P MWTTRW5ITVJ?
KMS-12-PE M{XBZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzhTZpKSzVyPUe2MlI1KG6P MnPEV2FPT0WU
KP-N-YS MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\RTWM2OD15Nj63OEBvVQ>? NHrH[IJUSU6JRWK=
ALL-PO MmT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTd5Lk[2JI5O MX;TRW5ITVJ?
EW-13 MnHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTJd5RLUUN3ME23O{44PiCwTR?= MUHTRW5ITVJ?
EW-11 NYDQSGJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXn4S4xXUUN3ME23PE42OiCwTR?= MW\TRW5ITVJ?
SK-N-FI MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnkTWM2OD16MD6yJI5O M2PwXHNCVkeHUh?=
CAL-148 NVfLTnprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPPTWM2OD16MT64OEBvVQ>? MWjTRW5ITVJ?
RL MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\5TWM2OD16Nj6wPUBvVQ>? MVLTRW5ITVJ?
AM-38 Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nadmlEPTB;OEiuNFghdk1? NHfF[pRUSU6JRWK=
RH-1 M2\ROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\oTIg3UUN3ME25PU45PSCwTR?= NIj0WFRUSU6JRWK=
NCI-H1770 Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vqTmlEPTB;MUCyMlQ6KG6P MYjTRW5ITVJ?
SIG-M5 M1\NbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTFyNT6wOkBvVQ>? MXrTRW5ITVJ?
GR-ST M1HaPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\u[FBOUUN3ME2xNVMvOzRibl2= NVzlcoFbW0GQR1XS
ST486 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2q3VWlEPTB;MUG0MlA3KG6P NYLU[XRYW0GQR1XS
NCI-H1650 M3TUN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWG5NlFbUUN3ME2xNVUvOjlibl2= MWrTRW5ITVJ?
MHH-CALL-2 NEnie5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\ZVJlKSzVyPUGxOU44KG6P M2PUTXNCVkeHUh?=
BV-173 NVn5cVhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTF{Mj63NUBvVQ>? NVXr[phmW0GQR1XS
MC116 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjxdY1KSzVyPUG0PE45PSCwTR?= NG\udnlUSU6JRWK=
NCI-H524 MoDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTF3OT6xJI5O NGTLeXlUSU6JRWK=
SCLC-21H MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDmTWM2OD1zNUmuOFEhdk1? MVHTRW5ITVJ?
NCI-H1304 M1v5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTF4OT6yNUBvVQ>? NXLydHd7W0GQR1XS
NCI-H510A MmTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGX2cIJKSzVyPUG4OU4{PyCwTR?= Mlz3V2FPT0WU
NCI-H209 Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTF7Nj61NkBvVQ>? Mm\jV2FPT0WU
KM-H2 NYPhXItrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTHdnJmUUN3ME2xPVcvODVibl2= M4q3TXNCVkeHUh?=
NCI-H1395 NXfXbnFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XXS2lEPTB;MkGwMlE{KG6P NEPXUI5USU6JRWK=
NCI-H1155 M1q3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTJ|MD6zNkBvVQ>? Mly1V2FPT0WU
COR-L279 NUPt[4NrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXOcWpKSzVyPUK1Nk4yPyCwTR?= M2\YTnNCVkeHUh?=
NCI-H1299 NH;RbI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzQSlJ7UUN3ME2yOlEvPzFibl2= MlviV2FPT0WU
EW-22 NFXWXoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrITWM2OD1{NkOuO|Uhdk1? M3KzUnNCVkeHUh?=
SK-MEL-2 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJ6MT65JI5O NUTmXmg3W0GQR1XS
KASUMI-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoT6TWM2OD1{OEOuNFUhdk1? NF7QXmtUSU6JRWK=
NCI-H187 Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjITWM2OD1{OEeuNFghdk1? MmDsV2FPT0WU
NCI-H2171 MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDvdpBKSzVyPUK4PE46OiCwTR?= NILUTlNUSU6JRWK=
LNCaP-Clone-FGC M{HwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;t[W5KSzVyPUK5OU4zPiCwTR?= MYjTRW5ITVJ?
NCI-H1522 MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LPOGlEPTB;M{C3MlA2KG6P NX35XpJ[W0GQR1XS
SCH MmnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTN{Mj6yNkBvVQ>? NHH4R2hUSU6JRWK=
THP-1 M{mybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfkN3NKSzVyPUOyNk43KG6P MlTxV2FPT0WU
SNU-C1 M13FOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jrXGlEPTB;M{[yMlA6KG6P NHf3TJNUSU6JRWK=
CA46 M{fx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fse2lEPTB;M{ezMlY{KG6P NUHyPVh5W0GQR1XS
NCI-H1963 M3TCPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:4SYJKSzVyPUO4Ok4yQSCwTR?= MoPtV2FPT0WU
DEL MoDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFm2SVNKSzVyPUO5NU4zPyCwTR?= MnPRV2FPT0WU
TUR MnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF34WJVKSzVyPUO5Ok43OSCwTR?= MkTjV2FPT0WU
NCI-H226 MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPBTWM2OD12MEOuNlMhdk1? NImxSoVUSU6JRWK=
COLO-668 NIXET41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPDSFNKSzVyPUSwN{42PyCwTR?= M17NTXNCVkeHUh?=
CPC-N MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\LcZZvUUN3ME20NFMvPzdibl2= MlftV2FPT0WU
NCI-H889 M2nhfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PqfWlEPTB;NE[xMlkzKG6P NEXPRWxUSU6JRWK=
J-RT3-T3-5 NH:5NllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTV|Mj61O{BvVQ>? NFHMbXJUSU6JRWK=
MSTO-211H NVrHU3BtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTV5ND6yOkBvVQ>? Mom2V2FPT0WU
SCC-15 NF\lZotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LKRmlEPTB;Nk[3MlQ4KG6P MUjTRW5ITVJ?
SUP-T1 M2PqPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXoS3pXUUN3ME22PFYvODRibl2= MUjTRW5ITVJ?
DMS-153 NFHPWphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3uTWM2OD15NE[uPFMhdk1? M{G5RnNCVkeHUh?=
MS-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTd3OT60NkBvVQ>? NX\rdJBLW0GQR1XS
TC-YIK M1G1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TMPGlEPTB;N{ixMlAyKG6P MV;TRW5ITVJ?
RPMI-8866 MoXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2q2cWlEPTB;MUCwOk4zQCEQvF2= MnrHV2FPT0WU
KY821 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;MTWM2OD1zMEO2MlA1KM7:TR?= NUfCTHdvW0GQR1XS
P31-FUJ MoizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;TOmlEPTB;MUGxNk44PSEQvF2= NHLLTpJUSU6JRWK=
COLO-824 MoC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTF{NkGuO|gh|ryP NIDEZotUSU6JRWK=
U-698-M MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTadJFKSzVyPUKyOlIvOTVizszN MUfTRW5ITVJ?
TE-441-T NV3BXFBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrlU4U6UUN3ME2yOVIyNjdizszN MUHTRW5ITVJ?
IMR-5 M3jMeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTN2MEmuOlIh|ryP MnXGV2FPT0WU
NCI-H1838 MkPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LVbWlEPTB;NEG4Ok4{OiEQvF2= MX7TRW5ITVJ?

... Click to View More Cell Line Experimental Data

体内研究 Bortezomib单一用药的抗癌作用已在多发性骨髓瘤的异种移植模型,成人白血病,肺癌,乳腺癌,前列腺癌,胰腺癌,头颈癌,和结肠癌,以及在黑色素瘤中得到证实。[2]在Lewis肺癌模型中,口服bortezomib (1.0 mg/ kg,每天),服用18天引起肿瘤生长延迟,并减少转移数量。Bortezomib单一用药, 高达5 mg/kg剂量时显著降低乳腺癌细胞的存活率。在前列腺癌小鼠异种移植模型中,Bortezomib (1.0 mg/kg,每周一次)用药4周减少60%肿瘤生长。1.0 mg/kg Bortezomib给药4周导致胰腺癌小鼠异种移植物生长减少72%或84%,并导致肿瘤细胞凋亡增加。1.0 mg/kg Bortezomib显著抑制人浆细胞瘤异种移植物生长,增加肿瘤细胞凋亡和总存活率,并减少肿瘤血管生成。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[4]

+ 展开

动力学法:

在典型的动力学试验中,2.00 mL试验缓冲液(20 mM HEPES,0.5 mM EDTA,0.035% SDS,pH 7.8) 和 Suc-Leu-Leu-Val-Tyr-AMC溶于DMSO,加入3 mL荧光比色皿中,并将比色皿放置于荧光分光光度计的夹套细胞皿座。反应温度通过循环水浴维持在37℃。反应溶液达到热平衡后(5 分钟),1 μL−10 μL储存酶溶液加入培养皿。伴随AMC 从多肽AMC底物裂解的反应进程通过440 nm (λex= 380 nm)下荧光发射的增加监测。
细胞实验:

[5]

+ 展开
  • Cell lines: 人多发性骨髓瘤细胞系U266
  • Concentrations: ~10 μM
  • Incubation Time: 2天
  • Method:

    通过测定细胞吸收 MTT染料的情况而测定 Bortezomib对 MM和 BMSC 生长的抑制情况。每孔使用10 μL 5 mg/mL MTT对培养48小时的细胞进行脉冲处理,至少处理4小时, 随后加入100 μL 含0.04 N HCl的异丙醇 。使用分光光度计在 570 nm处测定吸光值。


    (Only for Reference)
动物实验:

[3]

+ 展开
  • Animal Models: 人浆细胞瘤异种移植物RPMI 8226
  • Formulation: 生理盐水
  • Dosages: 1mg/kg
  • Administration: i.v.,一周两次,使用4周,然后一周一次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次加入纯溶剂:
2% DMSO+30% PEG 300+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 384.24
化学式

C19H25BN4O4

CAS号 179324-69-7
稳定性 powder
别名 LDP-341, MLM341

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01891968 Completed Leukemia M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. August 7, 2013 Phase 2
NCT01445405 Completed Carcinoma, Squamous|Head and Neck Cancer|Oral Cancer|Laryngeal Cancer|Pharyngeal Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 5, 2008 Phase 1
NCT02211755 Recruiting Neoplasms|Myelodysplastic Syndromes National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 30, 2014 Phase 1
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27, 2016 Phase 2
NCT00011778 Completed Squamous Cell Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 22, 2001 Phase 1
NCT02658396 Withdrawn Multiple Myeloma|Multiple Myeloma in Relapse|Refractory Multiple Myeloma Dana-Farber Cancer Institute|Genus Oncology, LLC|National Institutes of Health (NIH) June 2017 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • 回答:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

相关Proteasome产品

Tags: 购买Bortezomib (PS-341) | Bortezomib (PS-341)供应商 | 采购Bortezomib (PS-341) | Bortezomib (PS-341)价格 | Bortezomib (PS-341)生产 | 订购Bortezomib (PS-341) | Bortezomib (PS-341)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID